Advertisement

Topics

ImmunoCellular to suspend patient randomization in ICT-107 phase 3 trial

05:34 EDT 22 Jun 2017 | Pharmaceutical Business Review

ImmunoCellular Therapeutics has provided an update on the strategic review of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma.

Original Article: ImmunoCellular to suspend patient randomization in ICT-107 phase 3 trial

NEXT ARTICLE

More From BioPortfolio on "ImmunoCellular to suspend patient randomization in ICT-107 phase 3 trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...